PHA 301: Comprehensive Study Notes - Introductory Pharmacology

Basic Pharmacology Definitions & Safety Indices

  • Pharmacology:

    • The comprehensive science of drugs.

    • Encompasses drug origin, chemical properties, biological actions, mechanisms of action, therapeutic uses, and adverse effects.

  • Drug:

    • Any chemical substance—excluding nutrients or essential dietary requirements—that alters a physiological system or pathological state for the direct medical benefit of the recipient.

  • Pharmacokinetics (PK):

    • Defined fundamentally as what the body does to the drug.

    • Characterizes the full time course of drug disposition throughout the body, consisting of the four classical processes of ADME: Absorption, Distribution, Metabolism, and Excretion.

  • Pharmacodynamics (PD):

    • Defined fundamentally as what the drug does to the body.

    • Covers the biochemical and physiological actions of drugs, molecular target and receptor interactions, dose-response relationships, and the specific mechanisms underlying both therapeutic efficacy and toxicity.

  • Therapeutic Index (TI):

    • A quantitative metric utilized to evaluate the relative safety margin of a drug by contrasting the dose required for toxicity against the dose required for therapeutic efficacy.

    • Calculated clinically as the ratio of the median toxic dose to the median effective dose:     TI=TD50ED50TI = \frac{TD_{50}}{ED_{50}}

    • Calculated in preclinical animal investigations as the ratio of the median lethal dose to the median effective dose:     TI=LD50ED50TI = \frac{LD_{50}}{ED_{50}}

    • High Therapeutic Index:

    • Signifies a broad margin of therapeutic safety.

    • Example: Penicillin.

    • Low Therapeutic Index:

    • Represents a narrow therapeutic window where minimal fluctuations in plasma concentration can produce treatment failure or lethal toxicity.

    • Necessitates routine therapeutic drug monitoring (TDM).

    • Examples: Digoxin, Warfarin, Aminoglycosides, and Lithium.

Pharmacokinetics: Absorption and Distribution

  • Drug Absorption:

    • Defined as the translocation of a drug from its site of administration across biological barriers into systemic blood circulation.

    • Direct intravenous (IV) administration bypasses the absorption process entirely, delivering the complete administered dose directly into systemic circulation.

  • Physiological Mechanisms of Permeation:

    • Passive Diffusion:

    • Spontaneous migration of molecules down an electrochemical or concentration gradient without cellular expenditure of adenosine triphosphate (ATP).

    • Highly favors low-molecular-weight, lipophilic (lipid-soluble), and non-ionized chemical species.

    • Operates as the predominant transfer mechanism for the vast majority of therapeutic agents.

    • Facilitated Diffusion:

    • Carrier-mediated membrane transport operating down an electrochemical gradient.

    • Does not require metabolic energy (ATP).

    • Exhibits structural specificity and capacity-limited saturation kinetics.

    • Active Transport:

    • Specialized carrier-mediated translocation operating against an electrochemical or concentration gradient.

    • Requires continuous metabolic energy input (ATP hydrolysis) and exhibits saturability.

    • Examples: Levodopa, Methotrexate, and 5-Fluorouracil.

    • Endocytosis and Pinocytosis:

    • The cellular engulfment of macromolecular complexes across the membrane via vesicle formation.

    • Example: Vitamin B12B_{12} complexed with gastric intrinsic factor.

  • Key Determinants Governing Absorption:

    • pH and Ionization (pH-Partition Hypothesis):

    • Biological membranes are preferentially permeable to lipid-soluble, uncharged (non-ionized) forms of weak electrolytes.

    • Weak acids exist predominantly in their lipid-soluble, non-ionized state in acidic milieus, such as the gastric lumen at pH 1–31\text{–}3, promoting gastric absorption.

    • Weak bases exist predominantly in their lipid-soluble, non-ionized state in alkaline milieus, such as the small intestinal lumen at pH 7–87\text{–}8, facilitating intestinal absorption.

    • Surface Area and Vascular Perfusion:

    • Owing to an enormous absorptive surface area created by mucosal folds, villi, and microvilli, alongside dense capillary vascularization, the small intestine serves as the primary anatomical site of systemic absorption for both weak acids and weak bases, surpassing the stomach even for weak acids.

    • First-Pass Metabolism (Presystemic Elimination):

    • Orally administered drugs that traverse the gastrointestinal mucosal epithelium drain into the hepatic portal venous system and navigate the liver prior to reaching systemic circulation.

    • Robust hepatic enzyme extraction or intestinal wall degradation can drastically diminish systemic bioavailability.

    • Examples of drugs with high first-pass clearance: Propranolol, Lidocaine, Nitroglycerin, and Morphine.

    • Bioavailability (FF):

    • The fractional percentage of an administered drug dose that reaches the systemic circulation in an unaltered, chemically active form.

    • Intravenous drug administration exhibits an absolute bioavailability of 100%100\% (F=1.0F = 1.0).

  • Drug Distribution:

    • The reversible dispersion of drug molecules from the systemic intravascular compartment into the interstitial and intracellular fluids of body tissues.

    • Plasma Protein Binding:

    • Acidic drugs bind predominantly to circulating serum albumin.

    • Basic drugs bind primarily to α1\alpha_1-acid glycoprotein.

    • Only the unbound (free) drug fraction possesses the physical capacity to diffuse through vascular membranes, interact with cellular targets, exert pharmacological activity, and undergo metabolic biotransformation and elimination.

    • Protein-bound drug remains restricted to the intravascular space, serving as an inert, circulating equilibrium reservoir.

    • Specialized Physiological Barriers:

    • Blood-Brain Barrier (BBB): Continuous non-fenestrated capillary endothelial cells bound by complex tight junctions and enveloped by perivascular astrocyte end-feet; strictly impedes hydrophilic or ionized molecules, admitting only highly lipophilic drugs or molecules that exploit endogenous carrier-mediated transporters.

    • Placental Barrier: Readily crossed by lipophilic substances via passive diffusion, exposing the developing fetus to potential chemical toxicities, pharmacological adverse reactions, and teratogenic risks.

    • Apparent Volume of Distribution (VdV_d):

    • A theoretical proportionality factor that correlates the total mass of drug present in the body to its concurrently measured plasma concentration (CpC_p):       Vd=Amount of drug in bodyCpV_d = \frac{\text{Amount of drug in body}}{C_p}

    • Low VdV_d (∼3–5 L\sim 3\text{–}5\,L): Denotes extensive sequestration within the vascular compartment, typically attributable to high plasma protein binding affinity or extremely bulky molecular size. Examples: Warfarin and Heparin.

    • High VdV_d (>40 L> 40\,L): Denotes extensive extravascular migration and deep tissue affinity, concentrating heavily into peripheral tissues or adipose depots beyond total body water volume. Examples: Chloroquine, Digoxin, and Amiodarone.

Drug Metabolism (Biotransformation)

  • Principles of Biotransformation:

    • The enzymatic biochemical modification of lipophilic compounds into distinctly polar, hydrophilic metabolites, facilitating their ultimate excretion by the renal or biliary systems.

    • The liver represents the primary metabolic organ, supplemented by the intestinal epithelium, pulmonary tissues, kidneys, and circulating blood plasma.

  • Comparison of Phase I and Phase II Reactions:

    • Mechanisms of Transformation:

    • Phase I (Functionalization): Introduces or unmasks a reactive polar functional group, such as −OH-OH, −NH2-NH_2, −SH-SH, or −COOH-COOH.

    • Phase II (Conjugation): Covalently couples the parent molecule or its Phase I metabolite with an endogenous, highly polar substrate.

    • Major Reaction Types:

    • Phase I: Oxidation (the most prevalent reaction), Reduction, and Hydrolysis.

    • Phase II: Glucuronidation (the most frequent Phase II pathway), Sulfation, Acetylation, Methylation, and Glutathione conjugation.

    • Primary Catalytic Enzymes:

    • Phase I: Cytochrome P450 (CYP450) monooxygenase enzyme superfamily (predominantly isoforms CYP3A4, CYP2D6, and CYP2C9) embedded within the microsomal membranes of the smooth endoplasmic reticulum.

    • Phase II: Specialized transferases, including microsomal UDP-glucuronosyltransferase (UGT), cytosolic N-acetyltransferase (NAT), and sulfotransferase (SULT).

    • Pharmacological and Therapeutic Outcomes:

    • Phase I: Metabolites may lose pharmacological activity (inactivation), maintain equivalent biological activity, gain elevated potency via prodrug bioactivation (e.g., the conversion of Enalapril into its active dicarboxylic acid metabolite Enalaprilat), or form chemically reactive, toxic intermediates.

    • Phase II: Almost invariably yields biologically inactive, intensely hydrophilic, and polar conjugates readily excreted in bile or urine.

    • Notable Clinical Exception: Morphine-6-glucuronide constitutes an active Phase II metabolite that exhibits greater analgesic potency than parent morphine.

  • CYP450 Enzyme Induction versus Inhibition:

    • Enzyme Induction:

    • Xenobiotics stimulate increased genetic transcription and de novo synthesis of CYP450 microsomal enzymes.

    • Results in an accelerated metabolic clearance of co-administered substrate drugs, precipitating decreased steady-state plasma concentrations and clinical therapeutic failure.

    • Mnemonic for Inducers (SCRAP GP):

      • S: Sulfonylureas

      • C: Carbamazepine

      • R: Rifampicin

      • A: Alcohol (chronic use)

      • P: Phenytoin

      • G: Griseofulvin

      • P: Phenobarbital

    • Enzyme Inhibition:

    • Pharmacological agents directly impair or competitively inhibit the catalytic activity of specific CYP450 isoenzymes.

    • Halts the normal metabolic degradation of co-administered substrate drugs, culminating in elevated systemic drug concentrations, prolonged pharmacological half-lives, and high risks of overt toxicity.

    • Mnemonic for Inhibitors (SICKFACES.COM):

      • S: Sodium valproate

      • I: Isoniazid

      • C: Cimetidine

      • K: Ketoconazole

      • F: Fluconazole

      • A: Alcohol (acute intoxication)

      • C: Chloramphenicol

      • E: Erythromycin

      • S: Sulfonamides

      • C: Ciprofloxacin

      • O: Omeprazole

      • M: Metronidazole

Drug Excretion: Renal and Hepatobiliary Routes

  • Definition of Excretion:

    • The irreversible physical removal of chemically unchanged therapeutic agents or their active/inactive biotransformation products from the body.

  • Renal Excretion Pathways:

    • The primary physiological route for eliminating hydrophilic compounds and small metabolites.

    • Glomerular Filtration:

    • Passive movement of circulating unbound (free) drugs across the fenestrated glomerular capillaries into Bowman's capsule space.

    • Highly restricted by molecular dimensions; drugs bound to plasma albumin are too large to pass through the filtration slits and remain in the capillary lumen.

    • Active Tubular Secretion:

    • Occurs specifically within the proximal convoluted tubule (PCT) via carrier-mediated, saturable, ATP-dependent transport systems.

    • Strips protein-bound drugs from plasma albumin by competitive mass action, secreting both free and bound fractions.

    • Organic Anion Transporters (OATs): Secrete acidic molecules, including Penicillins, Furosemide, Salicylates, and endogenous Uric acid. Clinically, Probenecid competitively blocks OAT-mediated penicillin secretion, deliberately prolonging systemic penicillin exposure.

    • Organic Cation Transporters (OCTs): Secrete basic therapeutic compounds, including Morphine, Dopamine, and Procainamide.

    • Passive Tubular Reabsorption:

    • Operates predominantly across the downstream distal convoluted tubule (DCT).

    • Lipophilic, non-ionized drugs freely back-diffuse across the tubular epithelium along a concentration gradient into the peritubular capillary blood.

    • Polar and fully ionized drugs are unable to penetrate the membrane and remain trapped inside the lumen for urinary excretion.

    • Ion Trapping in Clinical Toxicology:

    • Therapeutic manipulation of urine pH selectively converts weak electrolytes into membrane-impermeable ionized forms, trapping them in urine and preventing tubular reabsorption.

    • Urinary Alkalinization: Intravenous administration of Sodium Bicarbonate elevates tubular urine pH, driving weak acids (e.g., Aspirin, Phenobarbital) into their deprotonated, charged form, thereby accelerating urinary elimination during an overdose.

    • Urinary Acidification: Administration of Ammonium Chloride or Ascorbic Acid lowers tubular urine pH, driving weak bases (e.g., Amphetamines) into their protonated, charged cationic form, accelerating excretion.

  • Hepatobiliary Secretion and Gastrointestinal Elimination:

    • Involves the active, transporter-mediated translocation of drugs and metabolites across the hepatocyte canalicular membrane into bile, emptying via the common bile duct into the duodenum for fecal excretion.

    • Physicochemical Determinants for Biliary Secretion:

    • High molecular mass, typically exceeding 300–500 Da300\text{–}500\,Da (smaller polar substances are preferentially cleared by glomerular filtration).

    • Amphipathic molecular layout possessing strongly polar or ionic moieties, especially Phase II glucuronide and glutathione conjugates.

    • Canalicular Transport Mechanisms:

    • Mediated by ATP-binding cassette (ABC) primary active efflux transporters situated on the canalicular membrane.

    • P-glycoprotein (P-gp / MDR1): Transports amphipathic cations and bulky neutral molecules.

    • Multidrug Resistance-Associated Protein 2 (MRP2): Mediates the canalicular export of organic anions, particularly glucuronide and glutathione conjugates.

    • Breast Cancer Resistance Protein (BCRP): Secretes diverse conjugated and parent xenobiotics.

    • Enterohepatic Circulation (Recirculation):

    • A cyclic process wherein a parent drug undergoes hepatic Phase II glucuronidation and is excreted through the biliary tree into the small intestine.

    • Commensal microflora residing in the gut secrete the hydrolytic enzyme β\beta-glucuronidase, which cleaves the conjugated glucuronic acid moiety.

    • This reaction regenerates the lipid-soluble parent drug, which is subsequently reabsorbed across the intestinal enterocytes into the mesenteric venules and returned to the liver via the hepatic portal vein.

    • Clinical Impact: Enterohepatic recycling establishes an endogenous drug reservoir, substantially extending a drug's biological elimination half-life (t1/2t_{1/2}) and duration of pharmacological activity (e.g., Ethinylestradiol in oral contraceptives, Chloramphenicol, Morphine, Indomethacin, and Digoxin).

    • Drug-Drug Interaction: Administration of broad-spectrum oral antibiotics eradicates gut bacteria, eliminating intestinal β\beta-glucuronidase activity, which prevents deconjugation, promotes rapid fecal wasting of the conjugated drug, and risks unintended contraceptive failure.

    • Direct Fecal Elimination:

    • Non-absorbed fractions of orally administered drugs travel down the lumen of the gastrointestinal tract and are evacuated unaltered in the feces.

Quantitative Pharmacokinetics: Clearance, Half-Life, and Steady-State Kinetics

  • Drug Clearance (CL):

    • Defined as the theoretical volume of plasma entirely cleared of drug per unit of time (expressed in units of mL/min\text{mL/min} or L/hr\text{L/hr}).

    • Quantifies the efficiency of overall body elimination rather than the physical mass of drug cleared.

    • Total systemic clearance represents the sum of all individual clearing organs:     CLtotal=CLrenal+CLhepatic+CLotherCL_{\text{total}} = CL_{\text{renal}} + CL_{\text{hepatic}} + CL_{\text{other}}

    • Rate of elimination is calculated as clearance multiplied by plasma concentration:     Rate of Elimination=CL×Cp\text{Rate of Elimination} = CL \times C_p

    • Clearance as a function of the elimination rate constant (kek_e) and volume of distribution (VdV_d):     CL=ke×VdCL = k_e \times V_d

    • Clearance across an isolated vascular bed depends on organ blood perfusion (QQ) and the physiological extraction ratio (EE):     CLorgan=Q×ECL_{\text{organ}} = Q \times E

    • Under first-order elimination kinetics, clearance remains constant across the therapeutic dosing range because the physical rate of drug elimination rises in direct linear proportion to increases in plasma concentration (CpC_p).

  • Elimination Half-Life (t1/2t_{1/2}):

    • The duration of time necessary for the systemic plasma drug concentration (or absolute drug quantity in the body) to decline by exactly 50%50\% during the elimination phase.

    • Formulated quantitatively as:     t1/2=0.693×VdCLt_{1/2} = \frac{0.693 \times V_d}{CL}     t1/2=0.693ket_{1/2} = \frac{0.693}{k_e}

    • Determinants of Half-Life:

    • Half-life is directly proportional to the apparent volume of distribution (VdV_d) and inversely proportional to systemic clearance (CLCL).

    • Pathological conditions that lower clearance (e.g., chronic renal failure, hepatic cirrhosis) or pharmacological interactions (e.g., CYP450 inhibition), as well as physiological increases in VdV_d, cause a proportional prolongation of t1/2t_{1/2}.

    • Clinical Significance of t1/2t_{1/2}:

    • Dictates the therapeutic dosing frequency necessary to prevent excessive peak-to-trough plasma oscillations.

    • Governs the duration of continuous dosing needed to achieve steady-state plasma equilibrium (∼4 to 5\sim 4\text{ to }5 half-lives).

    • Dictates the terminal drug washout duration after therapy discontinuation (∼4 to 5\sim 4\text{ to }5 half-lives clears 93.75%–96.88%93.75\%\text{–}96.88\% of total body drug burden).

  • Fractional Elimination and Accumulation Across Elapsed Half-Lives:

    • 1 t1/21\,t_{1/2} Elapsed:

    • Percentage of drug eliminated (single dose): 50.0%50.0\%

    • Percentage of steady-state concentration (CssC_{ss}) reached: 50.0%50.0\%

    • 2 t1/22\,t_{1/2} Elapsed:

    • Percentage of drug eliminated (single dose): 75.0%75.0\%

    • Percentage of steady-state concentration (CssC_{ss}) reached: 75.0%75.0\%

    • 3 t1/23\,t_{1/2} Elapsed:

    • Percentage of drug eliminated (single dose): 87.5%87.5\%

    • Percentage of steady-state concentration (CssC_{ss}) reached: 87.5%87.5\%

    • 4 t1/24\,t_{1/2} Elapsed:

    • Percentage of drug eliminated (single dose): 93.75%93.75\%

    • Percentage of steady-state concentration (CssC_{ss}) reached: 93.75%93.75\% (Clinically accepted as having reached steady state)

    • 5 t1/25\,t_{1/2} Elapsed:

    • Percentage of drug eliminated (single dose): 96.88%96.88\% (Clinically considered completely eliminated)

    • Percentage of steady-state concentration (CssC_{ss}) reached: 96.88%96.88\% (Clinically accepted as having reached steady state)

  • Orders of Elimination Kinetics:

    • First-Order (Linear) Kinetics:

    • A constant fraction (percentage) of drug is eliminated per unit of time.

    • The absolute rate of elimination is directly proportional to plasma concentration (CpC_p).

    • Clearance (CLCL) and half-life (t1/2t_{1/2}) remain strictly constant and independent of total administered dose.

    • Governs the pharmacokinetic behavior of the vast majority of therapeutic drugs at clinical doses.

    • Zero-Order (Nonlinear / Saturation) Kinetics:

    • A constant absolute quantity (mass) of drug is cleared per unit of time.

    • Occurs because the available metabolizing enzymes or active transport mechanisms are entirely saturated.

    • The absolute rate of elimination is fixed and completely independent of plasma drug concentration (CpC_p).

    • Half-life increases with escalating doses; modest dosage increments lead to steep, disproportionate, non-linear surges in plasma drug levels and severe toxicity.

    • Mnemonic for Zero-Order Drugs (PEA):

      • P: Phenytoin

      • E: Ethanol

      • A: Aspirin (high therapeutic and toxic salicylate doses)

  • Steady-State Plasma Concentration (CssC_{ss}):

    • Defined as the dynamic pharmacokinetic equilibrium achieved during constant intravenous infusion or repeated fixed-interval dosing wherein the rate of systemic drug intake equals the rate of drug elimination:     Rate of Input=Rate of Elimination\text{Rate of Input} = \text{Rate of Elimination}

    • Average steady-state concentration (CssC_{ss}) calculation:     Css=F×DoseCL×τC_{ss} = \frac{F \times \text{Dose}}{CL \times \tau}

    • Maintenance Dose (MDMD) calculation:     MD=Css×CL×τFMD = \frac{C_{ss} \times CL \times \tau}{F}

    • Loading Dose (LDLD) calculation:     LD=Css×VdFLD = \frac{C_{ss} \times V_d}{F}

    • Parameter definitions: τ\tau (tau) represents the dosing interval, and FF represents fractional bioavailability.

    • Time to Achieve CssC_{ss}:

    • Depends solely upon the elimination half-life (t1/2t_{1/2}) of the agent, invariably requiring 4 to 5 t1/24\text{ to }5\,t_{1/2}.

    • Modifying dosage strength or continuous infusion rates changes the target plateau concentration (CssC_{ss} magnitude), but does not alter the absolute chronological time needed to reach that steady state.

    • Magnitude of CssC_{ss}:

    • Directly proportional to the drug dosing rate (F×Doseτ\frac{F \times \text{Dose}}{\tau}) and inversely proportional to total systemic clearance (CLCL).

    • Loading Dose versus Maintenance Dose:

    • A Loading Dose (LDLD) is an initial, elevated dose administered to immediately fill the apparent volume of distribution (VdV_d) and reach targeted therapeutic plasma levels rapidly without waiting across 4 to 54\text{ to }5 half-lives (essential for drugs with long half-lives like Digoxin and Amiodarone); it is governed strictly by VdV_d.

    • A Maintenance Dose (MDMD) is a recurrent dose designed to precisely replace the quantity of drug lost via ongoing clearance during each dosing interval (τ\tau) to maintain steady-state plateau levels; it is governed strictly by clearance (CLCL).

Pharmacodynamics: Targets, Receptors, and Dose-Response Relationships

  • Primary Molecular Targets for Drug Action:

    • Receptors:

    • Transmembrane or intracellular macromolecular targets that mediate cellular signaling.

    • Ligand-Gated Ion Channels: Mediate rapid synaptic transmission (e.g., Nicotinic acetylcholine receptor).

    • G-Protein Coupled Receptors (GPCRs): Regulate second messenger cascades (e.g., β\beta-adrenoceptors).

    • Enzyme-Linked Receptors: Possess intrinsic or recruited kinase activity (e.g., Insulin receptor).

    • Intracellular / Nuclear Receptors: Translocate to the nucleus to regulate gene transcription upon lipophilic ligand binding (e.g., Steroid hormone receptors).

    • Enzymes:

    • Direct competitive or allosteric inhibition of catalytic activity.

    • Examples: Aspirin irreversibly inhibits cyclooxygenase (COX); Enalapril competitively inhibits angiotensin-converting enzyme (ACE).

    • Ion Channels:

    • Direct physical occlusion or allosteric channel gating modification.

    • Examples: Lidocaine blocks voltage-gated Na+Na^+ channels; Amlodipine inhibits L-type voltage-gated Ca2+Ca^{2+} channels.

    • Carrier / Transport Proteins:

    • Interruption of active or facilitated secondary transport across plasma membranes.

    • Examples: Omeprazole inhibits the gastric parietal cell H+/K+H^+/K^+ ATPase proton pump; Furosemide inhibits the renal medullary Na+/K+/2Cl−Na^+/K^+/2Cl^- symporter.

  • Fundamental Receptor Pharmacodynamic Properties:

    • Affinity:

    • The thermodynamic attraction and propensity of a drug molecule to bind reversibly to its specific receptor binding domain.

    • Inversely related to the equilibrium dissociation constant (KdK_d); a smaller KdK_d reflects higher target affinity.

    • Intrinsic Activity (Efficacy):

    • The relative functional capacity of a bound drug-receptor complex to trigger conformational state transitions and activate downstream post-receptor biochemical pathways.

  • Classification of Receptor Ligands:

    • Full Agonist:

    • Displays high receptor affinity coupled with maximal intrinsic activity.

    • Produces the highest possible biological response (100% Emax⁡100\%\,E_{\max}) obtainable in that tissue system.

    • Partial Agonist:

    • Displays high receptor affinity coupled with submaximal intrinsic activity.

    • Incapable of producing a maximal biological response (<100% Emax⁡< 100\%\,E_{\max}) even when occupying 100%100\% of available receptors.

    • Functions as a competitive antagonist when co-administered alongside a full agonist by displacing the full agonist from receptor binding sites and blunting the maximal response.

    • Competitive Antagonist:

    • Binds reversibly to the orthosteric active site of a receptor without possessing intrinsic activity (intrinsic activity = 00).

    • Produces a parallel rightward shift in the agonist log concentration-response curve.

    • Increases the apparent median effective concentration (EC50EC_{50}), signifying a reduction in agonist potency, without depressing the maximal response (Emax⁡E_{\max}).

    • Reversible and surmountable by progressively escalating the ambient concentration of agonist.

    • Non-Competitive Antagonist:

    • Binds irreversibly to the primary active site via covalent bonds, or binds allosterically to a distinct secondary site to alter receptor conformation.

    • Depresses the maximal achievable tissue response (Emax⁡E_{\max}).

    • Insurmountable regardless of subsequent increases in agonist concentration.

  • Potency versus Efficacy:

    • Potency:

    • A relative measure of the drug concentration or dose required to elicit a biological response of a defined intensity.

    • Routinely quantified by the median effective concentration (EC50EC_{50}), the concentration required to elicit 50%50\% of that specific drug's maximal response.

    • A lower EC50EC_{50} reflects higher pharmacological potency.

    • Efficacy (Emax⁡E_{\max}):

    • The maximal therapeutic effect that a drug is physically capable of inducing at infinite concentration or maximal receptor occupancy.

    • In clinical pharmacology and patient management, efficacy is far more clinically decisive than potency, as therapeutic success depends upon achieving adequate biological response magnitude rather than minimizing the physical mass of the drug administered.